- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA reviewed the NDA for Disc Medicine, Inc., which required additional evidence on May 26, 2026.
8 reports, 3 independent
Updated Sep 1
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 8
- Developments
- 1
- Repetition
- 88%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reviewed the NDA for Disc Medicine, Inc., which required additional evidence on May 26, 2026.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA issued a Complete Response Letter (CRL) regarding Disc Medicine, Inc.'s bitopertin program.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- Ondine Biomedical Inc. is seeking a pre-NDA meeting with the FDA regarding LANTERN results while conducting clinical trials in the US and Canada.
Coverage
Newest first; wire copies grouped- stockhouse.com
- GlobeNewswireDisc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approva
- Insider MonkeyDisc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Disc Medicine, Inc. stands sixth on
- GlobeNewswireDisc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE